White Paper

A Risk-Based Approach To The Development Of An Injectable Combination Product

By Fran DeGrazio, former Chief Scientific Officer, Diane Paskiet, Director Scientific Affairs, and Peggy Frandolig, Sr. Manager Scientific Affairs, West Pharmaceutical Services, Inc.


Drug-device combination products (DDCPs), such as injectables, can consist of a biological product and a device, a drug and a biological product, or a drug, device, and a biological product or simply a drug and a device. DDCPs leverage new technologies that provide many advantages for patients, such as self-administration conveniences and safety, and, for payers, improved adherence. However, DDCPs are complex and challenging to develop.

This white paper examines how to establish a holistic approach to DDCP development and how to assess and manage risk throughout the development and approval process.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online

West Pharmaceutical Services, Inc.